The National Institutes of Health (NIH) awarded a phase I SBIR grant to Tango Biosciences in July 2025. This award will support the application of Tango Biosciences’ proprietary Avidimer platform for the development of protein tools that enhance the discovery of proximity inducing modalities such as molecular glues. The Avidimers developed in this program will generate proof-of-concept data for driving proximity of two protein targets resulting in a highly sensitive assay readout. Such tools may lead to the identification of new drugs for targeted protein degradation and beyond.
NIH Awards New SBIR Grant
More News and Events
-
News
Tango Biosciences Appoints Zachary Gurard-Levin, PhD to Board of Directors
Appointment Brings Over Ten Years as a CRO Executive Tango Biosciences, Inc., the premier contract research organization for custom affinity reagents by phage display, announced the appointment of Zachary Gurard-Levin, PhD, to its board of directors effective immediately. Gurard-Levin brings over two decades of experience in assay development and driving successful research programs for biotech […]
-
Event
ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Chicago, IL | May 12-15, 2025 Join Tango Biosciences at ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025! Booth CP3 This meeting attracts a highly targeted audience composed of experts and researchers in drug discovery and development. Visit the Tango Biosciences booth to talk to our experts in peptide therapeutics discovery, targeted protein degradation for PROTACs and molecular glues, […]
-
Event
AACR Annual Meeting
Chicago, IL | April 25-30, 2025 Attending the 2025 AACR Annual Meeting? Schedule a meeting with Tango Biosciences experts to talk about your upcoming needs in antibody and affinity reagent discovery! The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and […]